We proved through in vitro cell assay that wild-type IDH1 could inhibit the progression of RCC by inhibiting the proliferation and metastasis of RCC and promoting the apoptosis of RCC cell, and verified the inhibitory effect of IDH1 on RCC and the inhibitory effect of IDH1 substrate α-KG on tumor through in vivo experiments, preliminarily verified the possibility that α-KG could be used for the treatment of RCC. Here, IDH1 is linked to renal cell carcinoma.